PTPI (Petros Pharmaceuticals) Retained Earnings: $-112.28 Mil (As of Mar. 2026)


What is Petros Pharmaceuticals Retained Earnings?

Petros Pharmaceuticals PTPI +6.52% Retained Earnings is $-112.28 Mil as of Mar. 2026.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Petros Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2026 was $-112.28 Mil.

Petros Pharmaceuticals's quarterly retained earnings declined from Sep. 2025 ($-110.96 Mil) to Dec. 2025 ($-111.30 Mil) and declined from Dec. 2025 ($-111.30 Mil) to Mar. 2026 ($-112.28 Mil).

Petros Pharmaceuticals's annual retained earnings declined from Dec. 2023 ($-98.89 Mil) to Dec. 2024 ($-113.21 Mil) but then increased from Dec. 2024 ($-113.21 Mil) to Dec. 2025 ($-111.30 Mil).

Petros Pharmaceuticals  (OTCPK:PTPI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Petros Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals Retained Earnings Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -70.69 -90.73 -98.89 -113.21 -111.30

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.47 -110.04 -110.96 -111.30 -112.28

Petros Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-112.28 Mil mean?
Petros Pharmaceuticals (PTPI) has a Retained Earnings of $-112.28 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Petros Pharmaceuticals and its competitors.
Is Petros Pharmaceuticals' Retained Earnings too high?
Petros Pharmaceuticals' current Retained Earnings is $-112.28 Mil.
How does Petros Pharmaceuticals' Retained Earnings compare to STEK and KOAN?
Petros Pharmaceuticals' Retained Earnings of $-112.28 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Petros Pharmaceuticals and its competitors. Petros Pharmaceuticals's current Retained Earnings is $-112.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Retained Earnings of $-112.28 Mil. The current Retained Earnings is $-112.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Retained Earnings is $-112.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.